Annual Meeting

Type 1 diabetes work
gets special recognition

Kothari named a JLR early-career researcher
Isha Dey
March 1, 2019

For the love of science and a drive to understand disease, Vishal Kothari crossed continents and switched his career path from industry to academia.

Kothari grew up in India, where he completed a bachelor’s degree in pharmacy and a master’s degree in pharmacology. He then worked as a research scientist at Advinus Therapeutics Limited (now Eurofins Advinus), playing an important role in identifying drugs with improved efficacy for treating diabetes and cardiovascular diseases. This work provided him with much-needed experience, but given the global reach of diabetes and diabetes-associated cardiovascular diseases, Kothari wanted to investigate cardiovascular diseases at the molecular level as a way to pursue better prevention strategies.

Vishal KothariVishal Kothari left a career in industry to study cardiovascular diseases at the molecular level.

“Research in the industry is market-driven, but I wanted to do independent research,” he said.

This passion for scientific research spurred his move from his industry position in India to a Ph.D. program in nutritional sciences at Auburn University in Alabama, where his studies centered on mouse models of diet-induced insulin resistance and insulin signaling.

Since earning his Ph.D., Kothari has worked as a senior research fellow in Karin Bornfeldt’s lab at the University of Washington School of Medicine. His work focuses on the effects of changes in the function and composition of high-density lipoproteins in diabetes-associated risk of cardiovascular diseases such as heart attacks.

In addition to research, Kothari also mentors medical and undergraduate students, which he believes will help him to become an independent researcher. When not in the lab, he likes to travel and hang out with friends.

According to Bornfeldt, Kothari is notable for his “enthusiasm for research, his vision and dedication, his excellence in the lab and his team spirit.”

Addressing small HDLs in heart disease

Cardiovascular disease, or CVD, is the most common cause of death around the world. Factors such as hypertension, diabetes or hyperlipidemia increase the risk of heart disorders. According to the American Heart Association, at least 68 percent of people aged 65 or older with diabetes die from some form of heart disease, and 16 percent die of stroke.

High-density lipoprotein, or HDL, is associated with protection against CVD, perhaps in part by reducing inflammatory activation of macrophages, a key cell type in CVD. However, small populations of HDL also can cause cholesterol depletion and produce an inflammatory response by macrophages under certain conditions.

Vishal Kothari’s research is focused on understanding how small HDLs induce such effects and how Type 1 diabetes mellitus, or T1DM, contributes to this effect, since T1DM increases the risk of CVD including heart attacks. His study has shown that depleting cholesterol by HDL increases proinflammatory responses in macrophages both in vitro and in a transgenic mouse model. His findings further demonstrate that higher levels of small HDL populations, as observed in a mouse model of Type 1 diabetes, can exacerbate inflammatory activation of macrophages and that this process is dependent on a protease called ADAM17.

These findings help provide a better understanding of increased CVD risk in Type 1 diabetes and the possible factors mediating such effects.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Isha Dey

Isha Dey is a scientist at Thermo Fisher Scientific.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Meet Robert Helsley
Interview

Meet Robert Helsley

March 6, 2025

The Journal of Lipid Research junior associate editor studies chronic liver disease and was the first in his family to attend college.

Exploring life’s blueprint: Gene expression in development and evolution
In-person Conference

Exploring life’s blueprint: Gene expression in development and evolution

March 3, 2025

Meet Julia Zeitlinger and David Arnosti — two co-chairs of the ASBMB’s 2025 meeting on gene expression, to be held June 26-29, in Kansas City, Missouri.

ASBMB names 2025 fellows
Announcement

ASBMB names 2025 fellows

Feb. 17, 2025

American Society for Biochemistry and Molecular Biology honors 24 members for their service to the society and accomplishments in research, education, mentorship, diversity and inclusion and advocacy.

When Batman meets Poison Ivy
Science Communication

When Batman meets Poison Ivy

Feb. 13, 2025

Jessica Desamero had learned to love science communication by the time she was challenged to explain the role of DNA secondary structure in halting cancer cell growth to an 8th-grade level audience.

The monopoly defined: Who holds the power of science communication?
Essay

The monopoly defined: Who holds the power of science communication?

Feb. 12, 2025

“At the official competition, out of 12 presenters, only two were from R2 institutions, and the other 10 were from R1 institutions. And just two had distinguishable non-American accents.”

In memoriam: Donald A. Bryant
In Memoriam

In memoriam: Donald A. Bryant

Feb. 10, 2025

He was a professor emeritus at Penn State University who discovered how cyanobacteria adapt to far-red light and was a member of the American Society for Biochemistry and Molecular Biology for over 35 years.